TITLE:
MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)

CONDITION:
Colorectal Cancer

INTERVENTION:
MK0457, VX-680 (Aurora Kinase Inhibitor)

SUMMARY:

      Study with an investigational drug in patients with recurrent or non-responsive colorectal
      cancer or other advanced solid tumors.

      This is an early phase trial and some specific protocol information is proprietary and not
      publicly available at this time. (Full information is available to trial participants).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  In Part I, patients who are at least 18 years of age with advanced solid tumors and
             colorectal cancer will be eligible for the first part of this study. Patient must
             have recovered from and be at least 3 weeks from previous cancer treatment.

          -  In Part II, only patients with colorectal cancer will be eligible to participate. The
             patients may have received up to 3 prior treatments for their colorectal cancer.
             Patients must have recovered from and be at least 3 weeks from previous therapy.

        Exclusion Criteria:

          -  Patients who have had treatment with any investigational drug within the past 30
             days.

          -  Patients who have certain types of blood cancers such as leukemia or lymphoma.

          -  Patients who have uncontrolled congestive heart failure (CHF), chest pain, or heart
             attack within the past 3 months.

          -  Patient is pregnant or nursing.
      
